# Deep Research Report: grok-4-1-fast-web-search
**Status:** ✅ Success | **Attempts:** 1/5 | **Run ID:** 58220593 | **Time:** 32.75s | **Cost:** $0.00544
--------------------------------------------------------------------------------

**The selection of chemotherapy regimens based on tumor molecular subtyping involves a nuanced risk-benefit analysis, weighing the anticipated antitumor efficacy (e.g., pathologic complete response [pCR] rates, progression-free survival) against the risk of myelosuppression (primarily grade 3/4 neutropenia, anemia, or thrombocytopenia), which can lead to dose delays, reductions, infections, or treatment discontinuation.[[2]](https://pmc.ncbi.nlm.nih.gov/articles/PMC12635783)**

**Key factors balancing these considerations include:**

1. **Tumor Molecular Subtype-Specific Response Predictions**:
   - Subtypes with high predicted chemo sensitivity (e.g., triple-negative breast cancer [TNBC], HER2-enriched breast cancer, CMS1/CMS3 in colorectal cancer [CRC], or certain acute myeloid leukemia [AML] genotypes like NPM1-mutated) justify regimens with higher myelosuppression risk if pCR/response rates exceed 20-50% in subtype-stratified trials.[[3]](https://tcr.amegroups.org/article/view/100644/html)[[4]](https://www.mdpi.com/2072-6694/14/16/3876)
   - Low-response subtypes (e.g., luminal A breast cancer) favor de-escalation or omission of chemo to avoid unnecessary toxicity.[[5]](https://www.oncotarget.com/article/28002/text)

2. **Patient-Specific Myelosuppression Risk (from Nomograms/ML Models)**:
   - **Clinical factors**: Age (>65 years), low BMI/albumin, anemia (low hemoglobin/ANC), elevated tumor markers (CEA, CA19-9, CA125), comorbidities (diabetes, liver dysfunction), smoking, lung/bone marrow metastases.[[6]](https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2025.1704489/full)
   - **Treatment factors**: Regimen intensity (e.g., anthracycline-taxane doublets > single agents; FOLFOX/CAPOX in CRC; multiday regimens in SCLC), cycles planned, prior radiotherapy.[[7]](https://www.oncnursingnews.com/view/chemo-induced-myelosuppression-presentation-and-management-in-es-sclc)
   - Risk thresholds: Nomograms stratify low (<20%), intermediate (20-50%), high (>50%) CIM risk; primary G-CSF prophylaxis recommended for >20% grade 3/4 neutropenia risk per ASCO/ESMO guidelines.[[8]](https://www.magonlinelibrary.com/doi/10.12968/hmed.2025.0452)

3. **Supportive Care and Feasibility**:
   - Availability of G-CSF (pegfilgrastim) to mitigate neutropenia allows tolerance of higher-risk regimens in responsive subtypes.[[9]](https://ecancer.org/es/journal/article/1618-the-occurrence-and-risk-factors-of-chemotherapy-induced-neutropenia-in-patients-with-breast-cancer-not-receiving-primary-g-csf-prophylaxis)
   - Performance status (ECOG 0-1 tolerates more), baseline marrow reserve, and hospitalization access.

4. **Disease and Therapeutic Context**:
   - Curative intent (neoadjuvant/adjuvant) tolerates higher toxicity than palliative; early neutropenia may even predict better response in some settings (surrogate for drug exposure).[[10]](https://smw.ch/index.php/smw/article/view/3307/5620)[[11]](https://pmc.ncbi.nlm.nih.gov/articles/PMC10991990)
   - Alternatives: Switch to less myelosuppressive options (e.g., capecitabine vs oxaliplatin; targeted therapy if subtype-appropriate like anti-HER2).

**In practice, tools like nomograms integrate these for personalized decisions—e.g., high-response subtype + low-risk patient = aggressive regimen; high-response + high-risk = dose-adjusted or G-CSF-supported. Decision curve analysis supports net benefit across 10-90% risk thresholds.** This approach is prominent in breast cancer (PAM50 subtypes), CRC (CMS), and NSCLC, where subtype-guided trials inform trade-offs.[[12]](http://waocp.com/journal/index.php/apjcb/article/view/1993)

## Annotations (Inline Citations)
Citation [2] (Pos: 423-479): [Web] https://pmc.ncbi.nlm.nih.gov/articles/PMC12635783
Citation [3] (Pos: 951-1008): [Web] https://tcr.amegroups.org/article/view/100644/html
Citation [4] (Pos: 1008-1056): [Web] https://www.mdpi.com/2072-6694/14/16/3876
Citation [5] (Pos: 1187-1239): [Web] https://www.oncotarget.com/article/28002/text
Citation [6] (Pos: 1532-1625): [Web] https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2025.1704489/full
Citation [7] (Pos: 1810-1922): [Web] https://www.oncnursingnews.com/view/chemo-induced-myelosuppression-presentation-and-management-in-es-sclc
Citation [8] (Pos: 2120-2187): [Web] https://www.magonlinelibrary.com/doi/10.12968/hmed.2025.0452
Citation [9] (Pos: 2360-2549): [Web] https://ecancer.org/es/journal/article/1618-the-occurrence-and-risk-factors-of-chemotherapy-induced-neutropenia-in-patients-with-breast-cancer-not-receiving-primary-g-csf-prophylaxis
Citation [10] (Pos: 2880-2939): [Web] https://smw.ch/index.php/smw/article/view/3307/5620
Citation [11] (Pos: 2939-2996): [Web] https://pmc.ncbi.nlm.nih.gov/articles/PMC10991990
Citation [12] (Pos: 3568-3634): [Web] http://waocp.com/journal/index.php/apjcb/article/view/1993


## Sources
[1] https://www.cell.com/cancer-cell/fulltext/S1535-6108(24)00163-6
[2] https://d-nb.info/1271087499/34
[3] https://www.mdpi.com/2072-6694/14/16/3876
[4] https://pmc.ncbi.nlm.nih.gov/articles/PMC10991990
[5] https://www.researchgate.net/publication/373565748_Preliminary_metabolomics-based_predictive_models_for_myelosuppression_in_breast_cancer_patients_with_different_anthracycline_chemotherapy
[6] https://pmc.ncbi.nlm.nih.gov/articles/PMC12635783
[7] https://tcr.amegroups.org/article/view/100644/html
[8] https://www.researchgate.net/publication/388501745_Risk_Prediction_of_Myelosuppression_Following_First-line_Chemotherapy_in_Colorectal_Cancer
[9] https://www.oncnursingnews.com/view/chemo-induced-myelosuppression-presentation-and-management-in-es-sclc
[10] https://pmc.ncbi.nlm.nih.gov/articles/PMC11786037
[11] https://pmc.ncbi.nlm.nih.gov/articles/PMC12180452
[12] https://journals.sagepub.com/doi/10.1177/11795549251381678
[13] https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1679782/full
[14] https://www.mdpi.com/2076-3271/13/4/285
[15] https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2025.1704489/full
[16] http://waocp.com/journal/index.php/apjcb/article/view/1993
[17] https://e-century.us/files/ajcr/15/2/ajcr0163289.pdf
[18] https://www.mdpi.com/2072-6694/17/7/1163
[19] https://www.oncotarget.com/article/28002/text
[20] https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/bcp.70413?af=R
[21] https://ascpt.onlinelibrary.wiley.com/doi/10.1002/psp4.12963
[22] https://www.sciencedirect.com/science/article/pii/S1532046415001318
[23] https://www.magonlinelibrary.com/doi/10.12968/hmed.2025.0452
[24] https://smw.ch/index.php/smw/article/view/3307/5620
[25] https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1605421/pdf
[26] https://pubs.acs.org/doi/10.1021/acsomega.4c03641
[27] https://ecancer.org/es/journal/article/1618-the-occurrence-and-risk-factors-of-chemotherapy-induced-neutropenia-in-patients-with-breast-cancer-not-receiving-primary-g-csf-prophylaxis
[28] https://www.benchchem.com/product/b000688
[29] https://ascopubs.org/doi/10.1200/CCI.17.00022
[30] https://www.nature.com/articles/s41392-024-01823-2
[31] https://www.annalsofoncology.org/article/S0923-7534(19)55810-0/pdf
[32] https://www.spandidos-publications.com/10.3892/ol.2025.15377?text=fulltext
[33] https://pmc.ncbi.nlm.nih.gov/articles/PMC12140754
[34] https://www.jcancer.org/v16p1379.htm
